Nanomedical Theranostics in Cardiovascular Disease

Jun Tang; Mark E. Lobatto; Joanna C. Read; Aneta J. Mieszawska; Zahi A. Fayad; Willem J.M. Mulder

doi:10.1007/s12410-011-9120-6

Nanomedical Theranostics in Cardiovascular Disease

Jun Tang, Mark E. Lobatto, Joanna C. Read, Aneta J. Mieszawska, Zahi A. Fayad, Willem J.M. Mulder

Research output: Contribution to journal › Review article › peer-review

50 Scopus citations

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.

Original language	English
Pages (from-to)	19-25
Number of pages	7
Journal	Current Cardiovascular Imaging Reports
Volume	5
Issue number	1
DOIs	https://doi.org/10.1007/s12410-011-9120-6
State	Published - Feb 2012

Keywords

Cardiac molecular imaging
Cardiovascular disease
Diagnostics
Nanoparticle
Theranostics
Therapeutics

Access to Document

10.1007/s12410-011-9120-6

Cite this

@article{98cd1fe72e8543b7af1e58b57b93eda7,

title = "Nanomedical Theranostics in Cardiovascular Disease",

abstract = "Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.",

keywords = "Cardiac molecular imaging, Cardiovascular disease, Diagnostics, Nanoparticle, Theranostics, Therapeutics",

author = "Jun Tang and Lobatto, {Mark E.} and Read, {Joanna C.} and Mieszawska, {Aneta J.} and Fayad, {Zahi A.} and Mulder, {Willem J.M.}",

note = "Funding Information: Acknowledgments Support for this work was partially provided by the International Atherosclerosis Society (M.E.L). This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, as a Program of Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C, as well as by R01 EB009638 (Z.A.F.) and R01 CA155432 (W.J.M.M.).",

year = "2012",

month = feb,

doi = "10.1007/s12410-011-9120-6",

language = "English",

volume = "5",

pages = "19--25",

journal = "Current Cardiovascular Imaging Reports",

issn = "1941-9066",

publisher = "Current Medicine Group",

number = "1",

}

TY - JOUR

T1 - Nanomedical Theranostics in Cardiovascular Disease

AU - Tang, Jun

AU - Lobatto, Mark E.

AU - Read, Joanna C.

AU - Mieszawska, Aneta J.

AU - Fayad, Zahi A.

AU - Mulder, Willem J.M.

N1 - Funding Information: Acknowledgments Support for this work was partially provided by the International Atherosclerosis Society (M.E.L). This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, as a Program of Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C, as well as by R01 EB009638 (Z.A.F.) and R01 CA155432 (W.J.M.M.).

PY - 2012/2

Y1 - 2012/2

N2 - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.

AB - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.

KW - Cardiac molecular imaging

KW - Cardiovascular disease

KW - Diagnostics

KW - Nanoparticle

KW - Theranostics

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84873882639&partnerID=8YFLogxK

U2 - 10.1007/s12410-011-9120-6

DO - 10.1007/s12410-011-9120-6

M3 - Review article

AN - SCOPUS:84873882639

SN - 1941-9066

VL - 5

SP - 19

EP - 25

JO - Current Cardiovascular Imaging Reports

JF - Current Cardiovascular Imaging Reports

IS - 1

ER -

Nanomedical Theranostics in Cardiovascular Disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this